IDEAYA Biosciences Raises $300M in Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: seekingalpha
- Offering Size: IDEAYA Biosciences has announced an underwritten public offering aimed at raising approximately $300 million by selling 5.56 million shares of common stock at a price of $27 per share, indicating strong market demand for the company.
- Pre-Funded Warrants: The company is also issuing pre-funded warrants to purchase an additional 5.56 million shares at $26.9999 per warrant with a nominal exercise price of $0.0001 per share, enhancing its capital-raising capabilities.
- Underwriter's Option: IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1.67 million shares at the public offering price, providing the company with additional financial flexibility.
- Transaction Timeline: The transaction is expected to close on or about June 10, 2026, subject to customary closing conditions, reflecting the company's robust planning in capital operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 31.260
Low
30.00
Averages
49.86
High
79.00
Current: 31.260
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Biosciences Appoints New Chairman
- Board Appointments: IDEAYA Biosciences has appointed Yujiro S. Hata as Chairman of the Board, who also serves as President and CEO, indicating the company's commitment to leadership stability aimed at advancing its clinical-stage oncology initiatives.
- Independent Director Role: Terry Rosen has been appointed as the Lead Independent Director, which not only enhances the board's independence but may also improve corporate governance, thereby boosting investor confidence.
- Stock Performance: IDEAYA shares closed up 1.12% at $30.57 on Tuesday, reflecting a positive market reaction to the new leadership, although pre-market trading showed a slight decline of 0.23% to $30.50.
- Market Outlook: The announcement of these appointments has generated optimism in the market regarding IDEAYA's future, particularly in its clinical advancements in oncology, which could attract more investor interest in its stock performance.
See More
IDEAYA Biosciences Elects New Chairman of the Board
- New Board Chairman: IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board, who also serves as President and CEO, reflecting the company's strong confidence in his leadership, which is expected to further drive growth in the precision medicine sector.
- Independent Director Appointment: Dr. Terry Rosen has been appointed as Lead Independent Director of IDEAYA's Board, indicating a commitment to enhancing governance independence, which may improve decision-making transparency and overall board effectiveness to support strategic objectives.
- Vision and Mission: Hata emphasized the importance of advancing cancer research and delivering breakthrough therapies, highlighting IDEAYA's commitment to addressing significant unmet medical needs in oncology, potentially attracting more investor interest in its clinical pipeline.
- Clinical Pipeline Development: IDEAYA focuses on product candidates related to synthetic lethality and antibody-drug conjugates, and as preparations for commercialization progress, the company is expected to generate new revenue streams and maintain a leading position in the precision oncology field.
See More
IDEAYA Biosciences Appoints New Chairman
- Board Appointment: IDEAYA Biosciences announced the election of Yujiro S. Hata as the new Chairman of the Board, who also serves as President and CEO, reflecting the company's confidence in his leadership to drive strategic growth.
- Leadership Acknowledgment: Dr. Terry Rosen, Lead Independent Director, noted that Hata's vision and leadership have been pivotal in IDEAYA's evolution from a startup to a leading precision medicine oncology company, underscoring his importance in future developments.
- Clinical Pipeline Expansion: IDEAYA is committed to developing transformative therapies for cancer, boasting a robust clinical pipeline and preparing for potential commercial launches, which will help address unmet medical needs and enhance the company's competitive position in the market.
- Forward-Looking Statements: The company’s forward-looking statements highlight its strategic goals in cancer research and therapy development, acknowledging the uncertainties inherent in drug development while remaining committed to innovation and commercialization efforts to improve clinical outcomes for patients.
See More
IDEAYA Launches Phase 1 Trial for IDE892 in Cancer Treatment
- Trial Initiation: IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 clinical trial evaluating IDE892 in combination with IDE397 for MTAP-deleted solid tumors, particularly focusing on non-small cell lung cancer and pancreatic cancer, showcasing the company's leadership in precision medicine.
- Combination Therapy Advantage: Preclinical studies indicate that the dual inhibition of PRMT5 and MAT2A with IDE892 and IDE397 results in potent anti-tumor activity in MTAP-deleted tumor models, achieving complete and durable responses at well-tolerated doses, suggesting this combination could set a new standard for treating these cancers.
- Market Demand: MTAP deletion occurs in approximately 15% of all solid tumors, with 15-20% in non-small cell lung cancer and up to 40% in pancreatic cancer, highlighting a significant unmet need and market opportunity for new therapies in this area.
- Strategic Collaboration: IDEAYA has entered into a clinical collaboration with Roche to evaluate the combination of IDE892 with RG6505, targeting genetic co-alterations of MTAP and KRAS, further strengthening the company's strategic positioning in precision oncology.
See More
IDEAYA Biosciences Launches IDE892 Clinical Trial for MTAP-Deleted Cancers
- Trial Commencement: IDEAYA Biosciences has announced the enrollment of the first patient in its clinical trial for IDE892 targeting MTAP-deleted tumors, which is expected to provide new treatment options for pancreatic cancer and non-small cell lung cancer patients lacking effective therapies.
- Drug Properties Advantage: IDE892 demonstrates over 1,400-fold selective MTA-PRMT5 binding capability, aimed at maximizing its therapeutic window and enabling rational combinations with IDE397 and pan-RAS inhibitors, thereby enhancing anti-tumor efficacy and prolonging patient survival.
- Significant Market Need: MTAP deletion occurs in approximately 40% of pancreatic cancers and 15% of non-small cell lung cancers, highlighting the substantial market opportunity for developing new precision therapies targeting these tumors due to the current lack of effective treatments.
- Broad Collaboration Prospects: IDEAYA's collaboration with Roche to evaluate the potential of combining IDE892 with RG6505 targets the genetic co-alterations of MTAP and KRAS, further expanding its influence in the precision medicine field.
See More
IDEAYA Biosciences Completes Public Offering Raising $345 Million
- Offering Size: IDEAYA Biosciences successfully closed its public offering of 7,222,225 shares at $27.00 per share, raising approximately $345 million in gross proceeds, significantly enhancing its financial capacity to support ongoing R&D initiatives.
- Underwriter Performance: The offering was managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting strong market confidence in IDEAYA and laying the groundwork for future capital market activities.
- Registration Compliance: The public offering was conducted under an automatically effective shelf registration statement on Form S-3, ensuring compliance and streamlining the offering process, which enhances investor trust.
- Strategic Development: IDEAYA is focused on precision oncology, and the proceeds from this offering will be used to advance its research in synthetic lethality and antibody-drug conjugates (ADCs), further solidifying its market position in cancer therapeutics.
See More
IDEAYA Biosciences Appoints New Chairman
- Board Appointments: IDEAYA Biosciences has appointed Yujiro S. Hata as Chairman of the Board, who also serves as President and CEO, indicating the company's commitment to leadership stability aimed at advancing its clinical-stage oncology initiatives.
- Independent Director Role: Terry Rosen has been appointed as the Lead Independent Director, which not only enhances the board's independence but may also improve corporate governance, thereby boosting investor confidence.
- Stock Performance: IDEAYA shares closed up 1.12% at $30.57 on Tuesday, reflecting a positive market reaction to the new leadership, although pre-market trading showed a slight decline of 0.23% to $30.50.
- Market Outlook: The announcement of these appointments has generated optimism in the market regarding IDEAYA's future, particularly in its clinical advancements in oncology, which could attract more investor interest in its stock performance.
See More
IDEAYA Biosciences Elects New Chairman of the Board
- New Board Chairman: IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board, who also serves as President and CEO, reflecting the company's strong confidence in his leadership, which is expected to further drive growth in the precision medicine sector.
- Independent Director Appointment: Dr. Terry Rosen has been appointed as Lead Independent Director of IDEAYA's Board, indicating a commitment to enhancing governance independence, which may improve decision-making transparency and overall board effectiveness to support strategic objectives.
- Vision and Mission: Hata emphasized the importance of advancing cancer research and delivering breakthrough therapies, highlighting IDEAYA's commitment to addressing significant unmet medical needs in oncology, potentially attracting more investor interest in its clinical pipeline.
- Clinical Pipeline Development: IDEAYA focuses on product candidates related to synthetic lethality and antibody-drug conjugates, and as preparations for commercialization progress, the company is expected to generate new revenue streams and maintain a leading position in the precision oncology field.
See More
IDEAYA Biosciences Appoints New Chairman
- Board Appointment: IDEAYA Biosciences announced the election of Yujiro S. Hata as the new Chairman of the Board, who also serves as President and CEO, reflecting the company's confidence in his leadership to drive strategic growth.
- Leadership Acknowledgment: Dr. Terry Rosen, Lead Independent Director, noted that Hata's vision and leadership have been pivotal in IDEAYA's evolution from a startup to a leading precision medicine oncology company, underscoring his importance in future developments.
- Clinical Pipeline Expansion: IDEAYA is committed to developing transformative therapies for cancer, boasting a robust clinical pipeline and preparing for potential commercial launches, which will help address unmet medical needs and enhance the company's competitive position in the market.
- Forward-Looking Statements: The company’s forward-looking statements highlight its strategic goals in cancer research and therapy development, acknowledging the uncertainties inherent in drug development while remaining committed to innovation and commercialization efforts to improve clinical outcomes for patients.
See More
IDEAYA Launches Phase 1 Trial for IDE892 in Cancer Treatment
- Trial Initiation: IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 clinical trial evaluating IDE892 in combination with IDE397 for MTAP-deleted solid tumors, particularly focusing on non-small cell lung cancer and pancreatic cancer, showcasing the company's leadership in precision medicine.
- Combination Therapy Advantage: Preclinical studies indicate that the dual inhibition of PRMT5 and MAT2A with IDE892 and IDE397 results in potent anti-tumor activity in MTAP-deleted tumor models, achieving complete and durable responses at well-tolerated doses, suggesting this combination could set a new standard for treating these cancers.
- Market Demand: MTAP deletion occurs in approximately 15% of all solid tumors, with 15-20% in non-small cell lung cancer and up to 40% in pancreatic cancer, highlighting a significant unmet need and market opportunity for new therapies in this area.
- Strategic Collaboration: IDEAYA has entered into a clinical collaboration with Roche to evaluate the combination of IDE892 with RG6505, targeting genetic co-alterations of MTAP and KRAS, further strengthening the company's strategic positioning in precision oncology.
See More
IDEAYA Biosciences Launches IDE892 Clinical Trial for MTAP-Deleted Cancers
- Trial Commencement: IDEAYA Biosciences has announced the enrollment of the first patient in its clinical trial for IDE892 targeting MTAP-deleted tumors, which is expected to provide new treatment options for pancreatic cancer and non-small cell lung cancer patients lacking effective therapies.
- Drug Properties Advantage: IDE892 demonstrates over 1,400-fold selective MTA-PRMT5 binding capability, aimed at maximizing its therapeutic window and enabling rational combinations with IDE397 and pan-RAS inhibitors, thereby enhancing anti-tumor efficacy and prolonging patient survival.
- Significant Market Need: MTAP deletion occurs in approximately 40% of pancreatic cancers and 15% of non-small cell lung cancers, highlighting the substantial market opportunity for developing new precision therapies targeting these tumors due to the current lack of effective treatments.
- Broad Collaboration Prospects: IDEAYA's collaboration with Roche to evaluate the potential of combining IDE892 with RG6505 targets the genetic co-alterations of MTAP and KRAS, further expanding its influence in the precision medicine field.
See More
IDEAYA Biosciences Completes Public Offering Raising $345 Million
- Offering Size: IDEAYA Biosciences successfully closed its public offering of 7,222,225 shares at $27.00 per share, raising approximately $345 million in gross proceeds, significantly enhancing its financial capacity to support ongoing R&D initiatives.
- Underwriter Performance: The offering was managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting strong market confidence in IDEAYA and laying the groundwork for future capital market activities.
- Registration Compliance: The public offering was conducted under an automatically effective shelf registration statement on Form S-3, ensuring compliance and streamlining the offering process, which enhances investor trust.
- Strategic Development: IDEAYA is focused on precision oncology, and the proceeds from this offering will be used to advance its research in synthetic lethality and antibody-drug conjugates (ADCs), further solidifying its market position in cancer therapeutics.
See More
